Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_assertion type Assertion NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_head.
- NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_assertion description "[When associating the two urinary markers with different clinicopathological factors of the bladder cancer group, only SF exerted a significantly higher positivity rate at the invasive stage (100%) than the superficial stage (88.46%) as well as in transitional cell carcinoma (100% thansquamous cell carcinoma type (87.5%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_provenance.
- NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_assertion evidence source_evidence_literature NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_provenance.
- NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_assertion SIO_000772 23724620 NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_provenance.
- NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_assertion wasDerivedFrom befree-20140225 NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_provenance.
- NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_assertion wasGeneratedBy ECO_0000203 NP756044.RAXWLF6PdEAn19L3lyQuBiw9ntsHO2qnLhUgMONd4TENo130_provenance.